Drug Profile


Alternative Names: Bec; MPC 1304; Sapresta

Latest Information Update: 08 May 1997

Price : $50

At a glance

  • Originator Maruko Seiyaku
  • Developer Maruko Seiyaku; Taiho Pharmaceutical
  • Class Antihypertensives; Dihydropyridines
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Angina pectoris; Hypertension

Most Recent Events

  • 08 May 1997 Launched for Hypertension in Japan (PO)
  • 22 Jan 1996 Registered for Angina pectoris in Japan (PO)
  • 22 Jan 1996 Registered for Hypertension in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top